But yeah, it was the clearest presentation yet on several points. An intriguing number on one of the slides for mean overall survival among patients receiving salvage treatment with Azixa: 111 days...and there may be another long-term surviver going (I couldn't tell if that was 10 months, then relapsed or 10 months and going). Explicit statement that the goal is to offer Azixa to the 170,000 patients with brain metastases, nor just the 10,000 with GBM. A lot of talk about potential partnerships in the anti-interferon program. Clarity that the HSP90 inhibitor phase 1 has passed the target blood concentration with no serious adverse effects, and is continuing only because they need to specify a dose-limiting toxicity. Some broad hints about potential first targets for the NAMPT-inhibitor drug.